Impairment in distinguishing spoken words from background noise may up Parkinson’s risk by 57% per 10 dB increase in the speech reception threshold, new research suggests. Medscape Medical News
Tag: Parkinson’s Disease
[ASAP] Dual GLP-1 and GIP Agonist Tirzepatide Exerted Neuroprotective Action in a Parkinson’s Disease Rat Model
[ASAP] Corilagin Attenuates Neuronal Apoptosis and Ferroptosis of Parkinson’s Disease through Regulating the TLR4/Src/NOX2 Signaling Pathway
Motor Functional Hierarchical Organization of Cerebrum and Its Underlying Genetic Architecture in Parkinsons Disease
Hierarchy has been identified as a principle underlying the organization of human brain networks. However, it remains unclear how the network hierarchy is disrupted in Parkinson’s disease (PD) motor symptoms and how it is modulated by the underlying genetic architecture. The aim of this study was to explore alterations in the motor functional hierarchical organization… Continue reading Motor Functional Hierarchical Organization of Cerebrum and Its Underlying Genetic Architecture in Parkinsons Disease
From mechanisms to future therapy: a synopsis of isolated REM sleep behavior disorder as early synuclein-related disease
Parkinson disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy are synucleinopathies, characterized by neuronal loss, gliosis and the abnormal deposition of α-synuclein in vulnerable areas…
Despite Early Promise GLP-1 Disappoints in Parkinson’s
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 study suggesting a potential role for GLP-1 agonists in PD. Medscape Medical News
[ASAP] Therapeutic Potential of Arimoclomol Nanomicelles: In Vitro Impact on Alzheimer’s and Parkinson’s Pathology and Correlation with In Vivo Inflammatory Response
[ASAP] Synergistic Anti-Ferroptosis with a Minimalistic, Peroxide-Triggered Carbon Monoxide Donor for Parkinson’s Disease
TAK-071 in Parkinson Disease With Cognitive Impairment
This phase 2 randomized clinical trial evaluates the safety and efficacy of TAK-071 compared with placebo on gait and cognition in participants with Parkinson disease with a history of falls and cognitive impairment.
Lewy body diseases and the gut
Gastrointestinal (GI) involvement in Lewy body diseases (LBDs) has been observed since the initial descriptions of patients by James Parkinson. Recent experimental and human observational studies raise the pos…